Surgical treatment in oligometastatic breast cancer

Simple item page
dc.contributor.authorVargas, Catalina
dc.contributor.authorMaiz, Cristobal
dc.contributor.authorElena Navarro, Maria
dc.contributor.authorOddo, David
dc.contributor.authorSanchez, Cesar
dc.contributor.authorBustos, Marisa
dc.contributor.authorCamus, Mauricio
dc.date.accessioned2025-01-23T21:13:39Z
dc.date.available2025-01-23T21:13:39Z
dc.date.issued2019
dc.description.abstractMetastatic breast cancer (MBC) management is based on systemic treatment (ST), while the local therapy role remains controversial. We present the case of a 36-year-old woman with a diagnosis of hormone receptor-positive and human epidermal growth factor receptor type 2-positive breast cancer and isolated sternal metastasis, who received neoadjuvant ST with complete remission and later primary tumour surgery. Oligometastatic patients are a subgroup of MBC that can benefit from aggressive local therapies, even with curative intent.
dc.fuente.origenWOS
dc.identifier.doi10.3332/ecancer.2019.931
dc.identifier.issn1754-6605
dc.identifier.urihttps://doi.org/10.3332/ecancer.2019.931
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101005
dc.identifier.wosidWOS:000469507500001
dc.language.isoen
dc.revistaEcancermedicalscience
dc.rightsacceso restringido
dc.subjectmetastatic breast cancer
dc.subjectstage IV breast cancer
dc.subjectsurgery
dc.subjectlocoregional treatment
dc.subjectoligometastatic
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSurgical treatment in oligometastatic breast cancer
dc.typeartículo
dc.volumen13
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas